PE20230382A1 - Nueva composicion farmaceutica para administracion de farmacos - Google Patents

Nueva composicion farmaceutica para administracion de farmacos

Info

Publication number
PE20230382A1
PE20230382A1 PE2022002543A PE2022002543A PE20230382A1 PE 20230382 A1 PE20230382 A1 PE 20230382A1 PE 2022002543 A PE2022002543 A PE 2022002543A PE 2022002543 A PE2022002543 A PE 2022002543A PE 20230382 A1 PE20230382 A1 PE 20230382A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
drug administration
new pharmaceutical
pharmaceutically acceptable
composition
Prior art date
Application number
PE2022002543A
Other languages
English (en)
Inventor
Jonas Savmarker
Robert Ronn
Andreas Fischer
Original Assignee
Orexo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2007306.0A external-priority patent/GB202007306D0/en
Priority claimed from GBGB2009905.7A external-priority patent/GB202009905D0/en
Priority claimed from GBGB2018901.5A external-priority patent/GB202018901D0/en
Application filed by Orexo Ab filed Critical Orexo Ab
Publication of PE20230382A1 publication Critical patent/PE20230382A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composicion farmaceuticamente aceptable, tal composicion esta en la forma de un polvo secado por aspersion que comprende una mezcla de: (a) una cantidad de dosis farmacologicamente efectiva de al menos un compuesto farmacologicamente activo; y (b) un material portador farmaceuticamente aceptable, tal material portador comprende una combinacion de un disacarido y un material polimerico.
PE2022002543A 2020-05-18 2021-05-18 Nueva composicion farmaceutica para administracion de farmacos PE20230382A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2007306.0A GB202007306D0 (en) 2020-05-18 2020-05-18 New pharmaceutical composition
GBGB2009905.7A GB202009905D0 (en) 2020-06-29 2020-06-29 New pharmaceutical composition
GBGB2018901.5A GB202018901D0 (en) 2020-12-01 2020-12-01 New pharmaceutical composition
PCT/GB2021/051191 WO2021234366A1 (en) 2020-05-18 2021-05-18 New pharmaceutical composition for drug delivery

Publications (1)

Publication Number Publication Date
PE20230382A1 true PE20230382A1 (es) 2023-03-06

Family

ID=76138084

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002543A PE20230382A1 (es) 2020-05-18 2021-05-18 Nueva composicion farmaceutica para administracion de farmacos

Country Status (24)

Country Link
US (2) US11737980B2 (es)
EP (2) EP4154866A1 (es)
JP (1) JP2023526098A (es)
KR (1) KR20230012502A (es)
CN (1) CN115666513A (es)
AU (1) AU2021276611A1 (es)
BR (1) BR112022023307A2 (es)
CA (1) CA3178769A1 (es)
CL (1) CL2022002979A1 (es)
CO (1) CO2022015183A2 (es)
DK (1) DK3962455T3 (es)
ES (1) ES2929818T3 (es)
HR (1) HRP20221361T1 (es)
HU (1) HUE060573T2 (es)
IL (1) IL297658A (es)
LT (1) LT3962455T (es)
MD (1) MD3962455T2 (es)
MX (1) MX2022014216A (es)
PE (1) PE20230382A1 (es)
PL (1) PL3962455T3 (es)
PT (1) PT3962455T (es)
RS (1) RS63725B1 (es)
SI (1) SI3962455T1 (es)
WO (1) WO2021234366A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202333658A (zh) * 2021-11-25 2023-09-01 瑞典商奥瑞克索股份公司 包含腎上腺素之新穎醫藥組合物
WO2023094818A1 (en) * 2021-11-25 2023-06-01 Orexo Ab Pharmaceutical composition comprising biopharmaceutical drug compounds
GB202117016D0 (en) * 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
WO2023187393A1 (en) 2022-03-31 2023-10-05 Hovione Scientia Limited Inhalation composite and carrier based formulation combination
TW202400219A (zh) * 2022-04-29 2024-01-01 香港商鵬躍醫藥科技有限公司 用於鼻內給藥的索馬魯肽及其鹽的藥物組合物
WO2024031148A1 (en) * 2022-08-11 2024-02-15 De Motu Cordis Pty Ltd Inhalable epinephrine formulation

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759520A (fr) 1969-11-28 1971-04-30 Aspro Nicholas Ltd Compositions d'aspirine
US5082669A (en) 1989-07-20 1992-01-21 Dainippon Pharmaceutical Co., Ltd. Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
SE8904296D0 (sv) 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
EP0657176B1 (en) 1993-12-06 2000-09-20 Takeda Chemical Industries, Ltd. Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
DE19518810A1 (de) 1995-05-26 1996-11-28 Bayer Ag Nasal-Applikator
US6398074B1 (en) 1998-03-10 2002-06-04 Valois S.A. Reservoir, reservoir filling method and device for dispensing fluid contained in the reservoir
PT1093818E (pt) * 1998-07-08 2006-07-31 Kirin Amgen Inc Preparacao em po para administracao nas mucosas contendo um medicamento polimerico
JP2000178184A (ja) 1998-12-17 2000-06-27 Lion Corp 粒状組成物、錠剤及び粒状組成物の製造方法
GB9908921D0 (en) 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
GB0003782D0 (en) 2000-02-17 2000-04-05 Dumex Ltd As Process
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US20020001617A1 (en) 2000-05-26 2002-01-03 Chang-Hyun Lee Rapidly disintegrating tablet and process for the manufacture thereof
FR2817847B1 (fr) 2000-12-08 2003-03-28 Tebro Dispositif de distribution de produit fluide ou pulverulent
IN192750B (es) 2000-12-15 2004-05-15 Ranbaxy Lab Ltd
LU90825B1 (en) 2001-09-06 2003-03-07 Iee Sarl Method for the determination of one or more parameters of a seat passenger
ITMI20012174A1 (it) 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
GB0201367D0 (en) 2002-01-22 2002-03-13 Ml Lab Plc Composition
AU2006207868A1 (en) 2002-03-20 2006-09-28 Alkermes, Inc. Method and apparatus for producing dry particles
DK1531794T3 (en) 2002-06-28 2017-08-28 Civitas Therapeutics Inc INHALABLE EPINEPHRIN
AU2003296954A1 (en) 2002-12-13 2004-07-09 The Regents Of The University Of California Analgesic combination comprising nalbuphine
CA2516816C (en) 2003-02-24 2012-02-07 Pharmaceutical Productions, Inc. Transmucosal drug delivery system
CA2524806C (en) 2003-05-07 2011-07-12 Akina, Inc. Highly plastic granules for making fast melting tablets
US20060115529A1 (en) 2003-05-07 2006-06-01 Seonghoon Jeong Fast-melting tablets having taste-masking and sustained release properties
ES2872350T3 (es) 2003-06-13 2021-11-02 Civitas Therapeutics Inc Polvos farmacéuticos de dosis baja para inhalación
CN100471497C (zh) 2003-06-25 2009-03-25 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻粉剂
TWI288649B (en) 2003-10-09 2007-10-21 Bioactis Ltd Powdery medicine dispensing device for nasal cavity
WO2005044186A2 (en) 2003-10-28 2005-05-19 Glaxo Group Limited Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
CN1640402A (zh) 2004-01-02 2005-07-20 广东奇方药业有限公司 一种稳定的纳洛酮粉针剂
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
US8642079B2 (en) 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
CN1615867A (zh) 2004-10-22 2005-05-18 北京阳光润禾科技有限公司 注射用盐酸纳洛酮冻干粉针制剂
CN1781479B (zh) 2004-12-02 2010-06-30 和记黄埔医药企业有限公司 一种马蔺子素分散体系及其制备方法
WO2006085101A2 (en) 2005-02-10 2006-08-17 Orexo Ab Pharmaceutical compositions useful in the transmucosal administration of drugs
KR101233235B1 (ko) 2005-08-26 2013-02-15 에스케이케미칼주식회사 초기 용출율이 개선된 프란루카스트 고체분산체의 약제학적조성물 및 그의 제조방법
WO2014007972A2 (en) * 2012-06-15 2014-01-09 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinphrine
US20070202163A1 (en) 2005-09-09 2007-08-30 Mutasem Rawas-Qalaji Fast-disintegrating epinephrine tablets for buccal or sublingual administration
CN1939358A (zh) 2005-09-30 2007-04-04 江西本草天工科技有限责任公司 肿节风分散片
CN1813739A (zh) 2005-11-25 2006-08-09 王颖 一种注射用盐酸纳美芬冻干粉针制剂
WO2007086039A1 (en) 2006-01-27 2007-08-02 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin A method of producing porous microparticles
WO2007096906A2 (en) 2006-02-27 2007-08-30 Panacea Biotec Ltd. Novel buccoadhesive compositions and process of preparation thereof
US20100226979A1 (en) 2006-03-21 2010-09-09 Jubilant Organosys Limited Taste Masked Phamaceutical Composition for Oral Solid Dosage form and Process for Preparing the Same Using Magnesium Aluminium Silicate
US20090208576A1 (en) 2006-03-31 2009-08-20 Gandhi Anilkumar S Orally Disintegrating Tablets
US20100034888A1 (en) 2006-09-15 2010-02-11 Hubert Clemens Pellikaan Granulate containing a pharmaceutically active substance and method for its manufacture
US20080269347A1 (en) 2006-09-28 2008-10-30 Azopharma, Inc. Epinephrine formulations
CA3027598C (en) 2007-01-10 2020-07-21 Board Of Regents The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
WO2009040595A1 (en) 2007-09-28 2009-04-02 Wockhardt Research Centre Multi-dose pharmaceutical composition of analgesic for nasal administration
JP5437232B2 (ja) 2008-03-11 2014-03-12 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
US20090246256A1 (en) 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Compositions and Methods for Transmucosal Delivery of Lofexidine
US20090264530A1 (en) 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
CN105770882A (zh) * 2009-05-20 2016-07-20 Aeras全球Tb疫苗基金会 稳定的经喷雾干燥的免疫原性的病毒组合物
BRPI1011229B8 (pt) * 2009-05-29 2021-05-25 Pearl Therapeutics Inc co-suspensão dispensável a partir de um inalador de dose medida compreendendo propelente, partículas de agente ativo e partículas em suspensão
EP2266563A1 (en) 2009-06-11 2010-12-29 Charité-Universitätsmedizin Berlin (Charité) Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
CA2765033C (en) 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
GB2472327B (en) 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
US9211282B2 (en) 2009-09-25 2015-12-15 Dr. Reddy's Laboratories Ltd. Formulations comprising triptan compounds
CN103153286A (zh) 2010-08-27 2013-06-12 沃泰克斯药物股份有限公司 药物组合物及其施用
CA2809666C (en) * 2010-08-30 2020-09-22 Michael M. Lipp Dry powder formulations and methods for treating pulmonary diseases
MY165826A (en) 2010-10-01 2018-05-17 Cipla Ltd Pharmaceutical composition
KR101965002B1 (ko) 2010-12-02 2019-08-13 아데어 파마슈티컬스 인코포레이티드 급속 분산성 과립, 구강 붕해성 정제 및 방법
BR112013020841B8 (pt) 2011-02-18 2021-11-30 Ying Ko Sai Processo para preparar produtos que compreendem ativos estabilizados e composições que compreendem os mesmos
DK2706982T4 (da) 2011-05-13 2021-05-10 Euro Celtique Sa Intranasale farmaceutiske dosisformer omfattende naloxon
CA2867236C (en) 2012-05-11 2017-02-28 Activus Pharma Co., Ltd. Organic compound nano-powder, method for producing the same and suspension
US9789071B2 (en) * 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
WO2014004400A2 (en) 2012-06-28 2014-01-03 The Governt. Of The Usa As Represented By The Secretary Of The Department Of Health & Human Services Nasal dry powder delivery system for vaccines and other treatment agents
FR3007992B1 (fr) 2013-07-05 2018-01-26 Aptar France Sas Dispositif de distribution de produit fluide ou pulverulent.
EP3041461A4 (en) 2013-09-03 2017-05-03 G2B Pharma Inc. Intranasal formulation for the treatment of cardiopulmonary resuscitation (cpr), cardiac life support (cls), anaphylaxis and/or anaphylactoid reactions
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
EP3082817A4 (en) 2013-12-18 2017-06-21 Aegis Therapeutics, LLC Compositions for drug administration
WO2015095644A1 (en) 2013-12-20 2015-06-25 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US20170014341A1 (en) * 2014-04-04 2017-01-19 Lam Therapeutics, Inc. An Inhalable Rapamycin Formulation for Treating Age-Related Conditions
US20190008759A1 (en) 2014-07-03 2019-01-10 Darren Rubin Safer and more effective methods of transmucosal delivery for raising blood pressure and stimulating the body
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP3174534A1 (en) 2014-08-01 2017-06-07 KRKA, d.d., Novo mesto Pharmaceutical formulation comprising an opioid agonist and an opioid antagonist prepared by melt granulation using lipid esters
CN107205936B (zh) 2014-10-08 2021-07-16 萨宝公司 包含至少一种通过喷雾干燥得到的增加制剂稳定性的干粉的组合物
ES2949137T3 (es) 2014-11-14 2023-09-25 Asoltech Srl Composición a base de coq10 campo de la invención
EP3025705B8 (en) 2014-11-25 2018-11-28 Sanofi Ilaç Sanayi ve Ticaret Anonim Sirketi Stable ivabradine formulations
CN104547220A (zh) 2014-12-30 2015-04-29 陈宏� 一种治疗儿童视觉疲劳的中药组合物及其制剂
US10166197B2 (en) 2015-02-13 2019-01-01 St. John's University Sugar ester nanoparticle stabilizers
WO2016133863A1 (en) 2015-02-17 2016-08-25 Eli Lilly And Company Nasal powder formulation for treatment of hypoglycemia
US20170189352A1 (en) 2015-03-13 2017-07-06 Par Pharmaceutical, Inc. Epinephrine formulations
CA2981991A1 (en) 2015-04-08 2016-10-13 Chang-Chun LING Pharmaceutical compositions of polyanionic and non-ionic cyclodextrin-based dendrimers and uses thereof
CA2984339A1 (en) 2015-05-01 2016-11-10 Civitas Therapeutics, Inc. Zolmitriptan powders for pulmonary delivery
US10039710B2 (en) 2015-09-18 2018-08-07 Insys Development Company, Inc. Epinephrine spray formulations
JP6953414B2 (ja) 2016-01-20 2021-10-27 フラリー パウダーズ エルエルシーＦｌｕｒｒｙ Ｐｏｗｄｅｒｓ，Ｌｌｃ 親油性成分を含む吸入に好適な分散性の噴霧乾燥粉末を製造する方法
ITUB20161027A1 (it) * 2016-02-24 2017-08-24 Altergon Sa Preparazioni farmaceutiche oromucosali ad elevata biodisponibilita’ a base di ciclodestrina e sucralosio
CA3017825C (en) 2016-03-16 2023-09-19 Omegatri As Powders and tablets comprising omega-3 fatty acid derivatives and methods for their production
US20170312226A1 (en) 2016-04-28 2017-11-02 Ascent Pharmaceuticals, Inc. Pharmaceutical dosage forms
US11903951B2 (en) 2016-06-03 2024-02-20 M et P Pharma AG Nasal pharmaceutical compositions with a porous excipient
US20190350881A1 (en) 2016-06-17 2019-11-21 Ys Pharmtech Stabilization of epinephrine formulations
BR112019002371A2 (pt) 2016-08-05 2019-06-04 Shin Nippon Biomedical Laboratories Ltd composições farmacêuticas
JP2020500081A (ja) 2016-09-28 2020-01-09 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． オピオイドを送達する経皮薬剤送達装置
WO2018064672A1 (en) 2016-09-30 2018-04-05 Opiant Pharmaceuticals, Inc. Treatment with intranasal naloxone
US20180092839A1 (en) 2016-10-03 2018-04-05 Lance L. Gooberman Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders
US20190262263A1 (en) 2016-11-09 2019-08-29 Opiant Pharmaceuticals, Inc. Compositions, devices and methods for the treatment of opioid-receptor-mediated conditions
US11458091B2 (en) 2016-11-18 2022-10-04 Opiant Pharmaceuticals, Inc. Compositions and methods for the treatment of opioid overdose
WO2018148382A1 (en) 2017-02-10 2018-08-16 Mucodel Pharma Llc Chemically stable compositions of a pharmaceutical active agent in a multi-chambered delivery system for mucosal delivery
WO2018195029A1 (en) 2017-04-17 2018-10-25 Insys Development Company, Inc. Epinephrine spray formulations
CA3071552A1 (en) 2017-08-20 2019-02-28 Formulex Pharma Innovations Ltd. Dry powder compositions for intranasal delivery
US20180193332A1 (en) 2017-10-09 2018-07-12 Adapt Pharma Operations Limited Low-temperature stable opioid antagonist solutions
US11077075B2 (en) 2018-01-10 2021-08-03 Hikma Pharmaceuticals Usa Inc. Methods of stabilizing epinephrine
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
CN112512506A (zh) 2018-06-13 2021-03-16 希克玛药物美国股份有限公司 肾上腺素喷雾制剂
US20230014352A1 (en) 2019-03-29 2023-01-19 The Regents Of The University Of California Inhaled statins as bronchodilators to improve lung function in respiratory diseases
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
US11400045B2 (en) 2020-03-16 2022-08-02 Nasus Pharma Ltd. Treatment with powdered intranasal epinephrine

Also Published As

Publication number Publication date
CO2022015183A2 (es) 2023-02-27
ES2929818T3 (es) 2022-12-02
EP3962455A1 (en) 2022-03-09
SI3962455T1 (sl) 2022-11-30
HRP20221361T1 (hr) 2023-01-06
US20220087938A1 (en) 2022-03-24
HUE060573T2 (hu) 2023-03-28
RS63725B1 (sr) 2022-12-30
KR20230012502A (ko) 2023-01-26
CA3178769A1 (en) 2021-11-25
PT3962455T (pt) 2022-10-13
BR112022023307A2 (pt) 2022-12-20
PL3962455T3 (pl) 2023-01-16
WO2021234366A1 (en) 2021-11-25
JP2023526098A (ja) 2023-06-20
MX2022014216A (es) 2022-12-07
AU2021276611A1 (en) 2022-12-15
CL2022002979A1 (es) 2023-05-12
IL297658A (en) 2022-12-01
LT3962455T (lt) 2022-10-25
DK3962455T3 (en) 2022-10-24
CN115666513A (zh) 2023-01-31
EP4154866A1 (en) 2023-03-29
US20240024244A1 (en) 2024-01-25
US11737980B2 (en) 2023-08-29
MD3962455T2 (ro) 2022-12-31
EP3962455B1 (en) 2022-08-31

Similar Documents

Publication Publication Date Title
PE20230382A1 (es) Nueva composicion farmaceutica para administracion de farmacos
UY27908A1 (es) Formulaciones y formas de dosificación para la administración controlada de topiramato
AR110986A2 (es) Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso
GB2596884A8 (en) Pharmaceutical composition
CL2022000033A1 (es) Composición farmacéutica para suministro nasal
ECSP088403A (es) Formulacion farmaceutica de absorción oral y su método de administracion
AR018410A1 (es) Uso de una composicion para la manufactura de un medicamento que se usa para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitentey/o episodios de asma cronico y metodo para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitente y/o episodios de asma cron
AR054064A1 (es) Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas
BRPI0512230A (pt) método para minimizar a retenção de pó sobre superfìcies
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
ECSP034826A (es) Método para fabricar una composición farmacéutica de dosis baja
PE20091672A1 (es) Nueva dosificacion y formulacion
AR018862A1 (es) Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion
AR074062A1 (es) Agonistas del receptor s1p para el tratamiento de la malaria cerebral y forma farmaceutica
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
CL2021001636A1 (es) Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar
MX2009006699A (es) Composicion y metodo para preparar tabletas oralmente disgregantes que contienen una alta dosis de ingredientes farmaceuticamente activos.
PE20130782A1 (es) Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
ECSP003685A (es) Formulaciones orales de liberacion controlada
AR068560A1 (es) Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamatorio no esteroide y un agente inhibidor de la xantino oxidasa utiles para el control y tratamiento de la gota artritis gotosa y enfermedades relacionadas
DOP2022000004A (es) Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad
MX2023005078A (es) Nuevas formas cristalinas de un compuesto inhibidor de kras g12c.
CR9324A (es) Preparación farmacéutica para la anticoncepción oral
MX2022013103A (es) Nueva composicion farmaceutica multiparticulada de tamsulosina y solifenacina.